Aug 29, 2012 by Brian Orelli, PhDA Biotech Field of Dreams?Monsanto and Alnylam hook up without spilling many details.
Aug 29, 2012 by Brian Orelli, PhDA Much-Needed Win for This Blockbuster DrugAn FDA advisory panel recommends expanding the use of Abbott's Humira.
Aug 28, 2012 by Brian Orelli, PhDThe FDA Puts the Brakes on Another HCV HopefulIdenix gets a second drug put on clinical hold.
Aug 28, 2012 by Brian Orelli, PhDIs the Long Road to Royalties Over for ImmunoGen?ImmunoGen is on the cusp of getting royalties from a drug it helped develop.
Aug 28, 2012 by Brian Orelli, PhDIt's FDA-Approved, but Will It Sell?Gilead gains approval of its quad pill Stribild.
Aug 27, 2012 by Brian Orelli, PhDForget the Hint of EfficacyEli Lilly should walk away from Alzheimer's disease drug solanezumab.
Aug 24, 2012 by Brian Orelli, PhDThe Most Epic Drug Failure. Ever.Bristol's acquisition of Inhibitex crashes and burns.
Aug 24, 2012 by Brian Orelli, PhDDo We Really Need Another Injected Rheumatoid Arthritis Drug?Probably not, but J&J and Glaxo are trying anyway.
Aug 23, 2012 by Brian Orelli, PhDLike a Sumo Wrestler, Pfizer Goes Big, With HelpPfizer and Mylan hook up to sell generics in Japan.
Aug 22, 2012 by Brian Orelli, PhDWe're Shrinking; It Could Be Worse Medtronic's defibrillator sales continue to decline.
Aug 22, 2012 by Brian Orelli, PhDAn Indirect Sign of Good Things to ComeAlexza gains EU manufacturing approval.
Aug 20, 2012 by Brian Orelli, PhDOrange Book BluesThe FDA updates its Orange Book, but Vascepa's entry is incomplete.
Aug 16, 2012 by Brian Orelli, PhDGuilt by Association = 30% Slaughter?Idenix's hepatitis C drug gets put on a clinical hold.
Aug 15, 2012 by Brian Orelli, PhD3 Companies Experiencing the Post-Approval BluesBut it's supposed to be a happy time.
Aug 15, 2012 by Brian Orelli, PhD3 Things to Watch at DendreonTo mount a comeback, these things have to fall into place.
Aug 14, 2012 by Brian Orelli, PhDIs This Spinoff Good for Investors?Elan plans to spin off its early-stage drug discovery business.
Aug 14, 2012 by Brian Orelli, PhDPfizer Bulks Up Before the BreakupOTC drug license from AstraZeneca implies it'll stay in the consumer health business.
Aug 13, 2012 by Brian Orelli, PhDCombo to Beat the Competition?Good idea, but the drugs have to work together.
Aug 10, 2012 by Brian Orelli, PhDA Growth-Free Quarter -- and That's OKSeattle Genetics keeps its eye on the pize.
